15P The analgesic compound palmitoylethanolamide reduces inflammation in human cardiomyocytes and vascular endothelial cells exposed to doxorubicin and anti-HER2 monoclonal antibody through PPAR-α and NLRP3-related pathways

S Buccolo,V Quagliariello,C Maurea,M Berretta,A Paccone,M De Laurentiis,N Maurea

doi:10.1016/j.annonc.2022.07.043

15P The analgesic compound palmitoylethanolamide reduces inflammation in human cardiomyocytes and vascular endothelial cells exposed to doxorubicin and anti-HER2 monoclonal antibody through PPAR-α and NLRP3-related pathways

S Buccolo, V Quagliariello + Show 5 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.043

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: University of Messina, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of Salerno

#N-acyl Phosphatidylethanolamine Phospholipase #anti-HER2 Monoclonal Antibody + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Palmitoylethanolamide (PEA) is an endogenous fatty acid mediator that is synthetized from membrane phospholipids by N-acyl phosphatidylethanolamine phospholipase D. It is a new analgesic drug with anti-inflammatory effects through the induction of PPAR-related pathways. We aimed to assess whether palmitoylethanolamide co-incubated during doxorubicin and trastuzumab, reduces anticancer drugs-related cardiotoxicity in cellular models.

Full Text